Decision on Zydus Cadila Covid-19 vaccine prices soon: Dr VK Paul

ZyCoV-D is the world's first plasmid DNA vaccine for Covid-19.;

Published On 2021-09-16 07:37 GMT | Update On 2021-09-16 07:37 GMT

New Delhi: The discussion on the pricing of Zydus Cadila's COVID-19 vaccine ZyCoV-D is underway, said Dr VK Paul, Member (Health) NITI Aayog on Tuesday.

"The discussion on the pricing of ZyCoV-D is ongoing. A decision will be taken soon. We are looking to include this vaccine in the national vaccination program," said Dr Paul in an exclusive interview with ANI.

Country's drugs regulator Drugs Controller General of India (

DCGI) approved the Zydus Cadila's vaccine for emergency use on August 20. According to sources, ZyCoV-D, a needle-free coronavirus vaccine, is likely to be available by early October.

It is the world's first plasmid DNA vaccine for Covid-19. It's a three-dose vaccine that will be administered on day zero, day 28, and day 56. The vaccine has been approved to be administered to adolescents between ages 12 and 18.

In an effort to expand the pool of COVID-19 vaccines in the country, Dr Paul said that Hyderabad-based pharmaceutical company, Biological E's COVID-19 vaccine Corbevax and COVID-19 mRNA vaccine are in the final stages of trial. "The other two vaccines are Biological E's COVID-19 vaccine, Corbevax, which is in the final stages of trial. Its manufacturing is already going on. Likewise, we have a fascinating mRNA vaccine from Genova. It is also in the final stages of the trial and this will also be available before the end of the year," said the NITI Aayog member.

He also said, "Bharat BioTech's nasal vaccine and also US firm Novavax's vaccine developed outside will now be stockpiled by Serum Institute of India. The emergency use authorisation (EUA) of this vaccine has not yet happened but our trials are near completion. So this will be another additional vaccine to the portfolio."Presently, Covishield, Covaxin, and Sputnik V vaccines are being administered to the eligible population above 18 years."

Dr Paul further said, "The other vaccines, which are already in the portfolio include Sputnik V. Progress has been somewhat slow, because this is a vaccine developed elsewhere. The technology is being transferred here. Sputnik V has been administered to about 8-9 lakh individuals already."

He added, "The availability of a pool of different vaccines is important because if the virus tries to play tricks with one form of vaccine, then at least we have other vaccines. Therefore, significant developments are now emerging. We are reaping the fruit of the hard work that has been done by the research and development teams as well as the industry, and all the effort that the government has put in, in this regard."India on Monday surpassed a "milestone" by surpassing 75 crore mark of India's cumulative COVID-19 vaccination coverage.

Dr Paul lauded the achievement of the country and said, "We are very proud. This achievement has been on the shoulders of two vaccines, which are being manufactured in India - Covishield and Covaxin. Of these, Covaxin is developed in India."

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Decision on Zydus Cadila Covid-19 vaccine prices soon: Dr VK Paul

ZyCoV-D is the world's first plasmid DNA vaccine for Covid-19.;

Similar News

Sigachi Pharma Plant explosion toll rises to 46, 8 still missing

Dr Reddy's Labs gets 7 USFDA observations for Srikakulam facility

JnJ gets USFDA priority review for TAR 200 NDA in high-risk non-muscle invasive bladder cancer

Zydus Asked to Revise Phase III Trial Protocol for Cough Syrup FDC After CDSCO Panel Review

Illegal sale of abortion kits: Show cause notice issued to 149 medical shops in Telangana

Granules India CEO Dr Kandiraju Venkata Sitaram Rao to step down

Torrent Pharma seeks CCI clearance to acquire majority stake in JB Pharma in Rs 19500 crore deal

Lupin receives USFDA observations for two Pithampur manufacturing units